Casein kinase 2, a versatile regulator of cell surviva

Molecular Biology

Volumn 46, Issue 3, 2012, Pages 381-390

  Volodina, Yu L ^a   Shtil, A A ^a  

^a N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

Author keywords

apoptosis; casein kinase 2; intracellular signaling; therapeutic target; tumor cells

Indexed keywords

EUKARYOTA;

EID: 84862328924     PISSN: 00268933     EISSN: 16083245     Source Type: Journal    
DOI: 10.1134/S0026893312020203     Document Type: Article

References (108)

1. Ahn N. G., Resing K. A. 2001. Toward the phosphoproteome. Nature Biotechnol. 19, 317-318.
2. Hopkins A. L., Groom C. R. 2002. The druggable genome. Nature Rev. Drug. Discov. 1, 727-730.
3. Burnett G., Kennedy E. P. 1954. The enzymatic phosphorylation of proteins. J. Biol. Chem. 211, 969-980.
4. Meggio F., Pinna L. A. 2003. One thousand and one substrates of protein kinase CK2? FASEB J. 17, 349-368.
5. Litchfield D. W. 2003. Protein kinase CK2: Structure, regulation and role in cellular decisions of life and death. Biochem. J. 369, 1-15.
6. St-Denis N. A, Litchfield D. W. 2009. Protein kinase CK2 in health and disease: From birth to death: the role of protein kinase CK2 in the regulation of cell proliferation and survival. Cell. Mol. Life Sci. 11-12, 1817-1829.
7. Lou D. Y., Dominguez I., Toselli P., et al. 2008. The alpha catalytic subunit of protein kinase CK2 is required for mouse embryonic development. Mol. Cell. Biol. 28, 131-139.
8. Mannowetz N., Kartarius S., Wennemuth G., Montenarh M. 2010. Protein kinase CK2 and new binding partners during spermatogenesis. Cell. Mol. Life Sci. 67, 3905-3913.
9. Bragdon B., Thinakaran S., Moseychuk O., et al. 2010. Casein kinase 2 beta-subunit is a regulator of bone morphogenetic protein 2 signaling. Biophys. J. 99, 897-904.
10. Dietz K. N., Miller P. J., Iyengar A. S., et al. 2011. Identification of serines 201 and 209 as sites of Pax3 phosphorylation and the altered phosphorylation status of Pax3-FOXO1 during early myogenic differentiation. Int. J. Biochem. Cell Biol. 43, 936-945.
11. Ryu S. W., Woo J. H., Kim Y. H., et al. 2006. Downregulation of protein kinase CKII is associated with cellular senescence. FEBS Lett. 580, 988-994.
12. Barz T., Ackermann K., Pyerin W. 2006. Control of methionine biosynthesis genes by protein kinase CK2-mediated phosphorylation of Cdc34. Cell. Mol. Life Sci. 63, 2183-2190.
13. An S., Kyoung M., Allen J. J., et al. 2010. Dynamic regulation of a metabolic multi-enzyme complex by protein kinase CK2. J. Biol. Chem. 285, 11093-11099.
14. Allada R., Meissner R. A. 2005. Casein kinase 2, circadian clocks, and the flight from mutagenic light. Mol. Cell. Biochem. 274, 141-149.
15. Bohana-Kashtan O., Pinna L. A., Fishelson Z. 2005. Extracellular phosphorylation of C9 by protein kinase CK2 regulates complement-mediated lysis. Eur. J. Immunol. 35, 1939-1948.
16. Filhol O., Cochet C. 2009. Cellular functions of protein kinase CK2: A dynamic affair. Cell. Mol. Life Sci. 66, 1830-1839.
17. Ahmad K. A., Wang G., Unger G., et al. 2008. Protein kinase CK2, a key suppressor of apoptosis. Adv. Enzyme Regul. 48, 179-187.
18. Trembley J. H., Wang G., Unger G., et al. 2009. Protein kinase CK2 in health and disease: CK2: A key player in cancer biology. Cell. Mol. Life Sci. 66, 1858-1867.
19. Ruzzene M., Pinna L. A. 2010. Addiction to protein kinase CK2: A common denominator of diverse cancer cells? Biochim. Biophys. Acta. 1804, 499-504.
20. Di Maira G., Brustolon F., Tosoni K., et al. 2008. Comparative analysis of CK2 expression and function in tumor cell lines displaying sensitivity vs. resistance to chemical induced apoptosis. Mol. Cell. Biochem. 316, 155-161.
21. Wang G., Ahmad K. A., Ahmed K. 2005. Modulation of death receptor-mediated apoptosis by CK2. Mol. Cell. Biochem. 274, 201-205.
22. Wang G., Unger G., Ahmad K. A., et al. 2005. Downregulation of CK2 induces apoptosis in cancer cells: A potential approach to cancer therapy. Mol. Cell. Biochem. 274, 77-84.
23. Slaton J., Unger G., Sloper D., et al. 2004. Induction of apoptosis by antisense CK2 in human prostate cancer xenograft model. Mol. Cancer Res. 2, 712-721.
24. Trembley J. H., Chen Z., Unger G., et al. 2010. Emergence of protein kinase CK2 as a key target in cancer therapy. Biofactors. 36, 187-195.
25. Hanif I. M., Hanif I. M., Shazib M. A., et al. 2010. Casein kinase II: An attractive target for anti-cancer drug design. Int. J. Biochem. Cell Biol. 42, 1602-1605.
26. Canton D. A., Litchfield D. W. 2006. The shape of things to come: An emerging role for protein kinase CK2 in the regulation of cell morphology and the cytoskeleton. Cell Signal. 18, 267-275.
27. Mehta A. 2008. Cystic fibrosis as a bowel cancer syndrome and the potential role of CK2. Mol. Cell. Biochem. 316, 169-175.
28. Singh N. N., Ramji D. P. 2008. Protein kinase CK2, an important regulator of the inflammatory response? J. Mol. Med. 86, 887-897.
29. Miyata Y. 2009. Protein kinase CK2 in health and disease: CK2: The kinase controlling the Hsp90 chaperone machinery. Cell. Mol. Life Sci. 66, 1840-1849.
30. Dominguez I., Sonenshein G. E., Seldin D. C. 2009. Protein kinase CK2 in health and disease. CK2 and its role in Wnt and NF-kappaB signaling: Linking development and cancer. Cell. Mol. Life Sci. 66, 1850-1857.
31. Vilk G., Weber J. E., Turowec J. P., et al. 2008. Protein kinase CK2 catalyzes tyrosine phosphorylation in mammalian cells. Cell Signal. 20, 1942-1951.
32. Olsten M. E., Litchfield D. W. 2004. Order or chaos? An evaluation of the regulation of protein kinase CK2. Biochem. Cell Biol. 82, 681-693.
33. Olsten M. E., Weber J. E., Litchfield D. W. 2005. CK2 interacting proteins: Emerging paradigms for CK2 regulation? Mol. Cell Biochem. 274, 115-124.
34. Hagemann C., Kalmes A., Wixler V., et al. 1997. The regulatory subunit of protein kinase CK2 is a specific A-Raf activator. FEBS Lett. 403, 200-202.
35. Lieberman S. L., Ruderman J. V. 2004. CK2 beta, which inhibits Mos function, binds to a discrete domain in the N-terminus of Mos. Dev. Biol. 268, 271-279.
36. Guerra B., Issinger O. G., Wang J. Y. 2003. Modulation of human checkpoint kinase Chk1 by the regulatory beta-subunit of protein kinase CK2. Oncogene. 22, 4933-4942.
37. Rodriguez F. A., Contreras C., Bolanos-Garcia V., Allende J. E. 2008. Protein kinase CK2 as an ectokinase: The role of the regulatory CK2beta subunit. Proc. Natl. Acad. Sci. U. S. A. 105, 5693-5698.
38. Montenarh M. 2010. Cellular regulators of protein kinase CK2. Cell Tissue Res. 342, 139-146.
39. Buchou T., Vernet M., Blond O., et al. 2003. Disruption of the regulatory beta subunit of protein kinase CK2 in mice leads to a cell-autonomous defect and early embryonic lethality. Mol. Cell Biol. 23, 908-915.
40. Xu X., Toselli P. A., Russell L. D., Seldin D. C. 1999. Globozoospermia in mice lacking the casein kinase II alpha' catalytic subunit. Nature Genet. 23, 118-121.
41. Vilk G., Saulnier R. B., St Pierre R., Litchfield D. W. 1999. Inducible expression of protein kinase CK2 in mammalian cells: Evidence for functional specialization of CK2 isoforms. J. Biol. Chem. 274, 14406-14414.
42. Guo C., Yu S., Davis A. T., et al. 2001. A potential role of nuclear matrix associated protein kinase CK2 in protection against drug induced apoptosis in cancer cells. J. Biol. Chem. 276, 5992-5999.
43. Wang H., Davis A., Yu S., Ahmed K. 2001. Response of cancer cells to molecular interruption of the CK2 signal. Mol. Cell Biochem. 227, 167-174.
44. Davis A. T., Wang H., Zhang P., Ahmed K. 2002. Heat shock mediated modulation of protein kinase CK2 in the nuclear matrix. J. Cell Biochem. 85, 583-591.
45. Yamane K., Kinsella T. J. 2005. CK2 inhibits apoptosis and changes its cellular localization following ionizing radiation. Cancer Res. 65, 4362-4367.
46. Kim H. R., Kim K., Lee K., et al. 2008. Inhibition of casein kinase 2 enhances the death ligand- and natural killer cell-induced hepatocellular carcinoma cell death. Clin. Exp. Immunol. 152, 336-344.
47. Lee S. W., Song Y. S., Lee S. Y., et al. 2011. Downregulation of protein kinase CK2 activity facilitates tumor necrosis factor-α-mediated chondrocyte death through apoptosis and autophagy. PLoS One. 6(4), e19163.
48. Parsons J. L., Dianova. I. I., Finch D., et al. 2010. XRCC1 phosphorylation by CK2 is required for its stability and efficient DNA repair. DNA Repair. 9, 835-841.
49. Ström C. E., Mortusewicz O., Finch D., et al. 2011. CK2 phosphorylation of XRCC1 facilitates dissociation from DNA and single-strand break formation during base excision repair. DNA Repair (Amsterdam). 10(9), 961-969.
50. Mani R. S., Yu Y., Fang S., et al. 2010. Dual modes of interaction between XRCC4 and polynucleotide kinase/phosphatase: Implications for nonhomologous end joining. J. Biol. Chem. 285, 37619-37629.
51. Ayoub N., Jeyasekharan A. D., Bernal J. A., Venkitaraman A. R. 2008. HP1-beta mobilization promotes chromatin changes that initiate the DNA damage response. Nature. 453, 682-686.
52. Kapoor M., Lozano G. 1998. Functional activation of p53 via phosphorylation following DNA damage by UV but not gamma radiation. Proc. Natl. Acad. Sci. U. S. A. 95, 2834-2837.
53. Keller D. M., Lu H. 2002. p53 serine 392 phosphorylation increases after UV through induction of the assembly of the CK2. hSPT16. SSRP1 complex. J. Biol. Chem. 277, 50206-50213.
54. Cox M. L., Meek D. W. 2010. Phosphorylation of serine 392 in p53 is a common and integral event during p53 induction by diverse stimuli. Cell Signal. 22, 564-571.
55. Meek D. W., Cox M. 2011. Induction and activation of the p53 pathway: A role for the protein kinase CK2? Mol. Cell Biochem. PMID: 21769452.
56. Bruins W., Zwart E., Attardi L. D., et al. 2004. Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. Mol. Cell Biol. 24, 8884-8894.
57. Hjerrild M., Milne D., Dumaz N., et al. 2001. Phosphorylation of murine double minute clone 2 (MDM2) protein at serine-267 by protein kinase CK2 in vitro and in cultured cells. Biochem. J. 355, 347-356.
58. Allende-Vega N., Dias S., Milne D., Meek D. 2005. Phosphorylation of the acidic domain of Mdm2 by protein kinase CK2. Mol. Cell Biochem. 274, 85-90.
59. Hubert A., Paris S., Piret J. P., et al. 2006. Casein kinase 2 inhibition decreases hypoxia-inducible factor-1 activity under hypoxia through elevated p53 protein level. J. Cell Sci. 119, 3351-3362.
60. Mottet D., Ruys S. P., Demazy C., et al. 2005. Role for casein kinase 2 in the regulation of HIF-1 activity. Int. J. Cancer. 117, 764-774.
61. Watabe M., Nakaki T. 2011. Protein kinase CK2 regulates the formation and clearance of aggresomes in response to stress. J. Cell Sci. 124, 1519-1532.
62. Hessenauer A., Schneider C. C., Götz C., Montenarh M. 2011. CK2 inhibition induces apoptosis via the ER stress response. Cell Signal. 23, 145-151.
63. Zheng Y., Qin H., Frank S. J., et al. 2011. A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway. Blood. 118(1), 156-166.
64. Tsuchiya Y., Asano T., Nakayama K., et al. 2010. Nuclear IKKbeta is an adaptor protein for IkappaBalpha ubiquitination and degradation in UV-induced NF-kappaB activation. Mol. Cell. 39, 570-582.
65. Chantome A., Pance A., Gauthier N., et al. 2004. Casein kinase II-mediated phosphorylation of NF-kappaB p65 subunit enhances inducible nitric-oxide synthase gene transcription in vivo. J. Biol. Chem. 279, 23953-23960.
66. Jacks K. A., Koch C. A. 2010. Differential regulation of mitogen- and stress-activated protein kinase-1 and -2 (MSK1 and MSK2) by CK2 following UV radiation. J. Biol. Chem. 285, 1661-1670.
67. Silva A., Yunes J. A., Cardoso B. A., et al. 2008. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J. Clin. Invest. 118, 3762-3774.
68. Di Maira G., Brustolon F., Pinna L. A., Ruzzene M. 2009. Dephosphorylation and inactivation of Akt/PKB is counteracted by protein kinase CK2 in HEK 293T cells. Cell. Mol. Life. Sci. 66, 3363-3373.
69. Ponce D. P., Maturana J. L., Cabello P., et al. 2011. Phosphorylation of AKT/PKB by CK2 is necessary for the AKT-dependent up-regulation of β-catenin transcriptional activity. J. Cell Physiol. 226, 1953-1959.
70. Ponce D. P., Yefi R., Cabello P., et al. 2011. CK2 functionally interacts with AKT/PKB to promote the β-catenin-dependent expression of survivin and enhance cell survival. Mol. Cell Biochem. PMID: 21735093.
71. Wang G., Ahmad K. A., Ahmed K. 2008. Impact of protein kinase CK2 on inhibitor of apoptosis proteins (IAPs) in prostate cancer cells. Mol. Cell Biochem. 316, 91-97.
72. Tapia J. C., Torres V. A., Rodriguez D. A., et al. 2006. Casein kinase 2 (CK2) increases survivin expression via enhanced beta-catenin-T cell factor/lymphoid enhancer binding factor-dependent transcription. Proc. Natl. Acad. Sci. U. S. A. 103, 15079-15084.
73. Barrett R. M., Colnaghi R., Wheatley S. P. 2011. Threonine 48 in the BIR domain of survivin is critical to its mitotic and anti-apoptotic activities and can be phosphorylated by CK2 in vitro. Cell Cycle. 10, 538-548.
74. Kang H., Jung J. W., Kim M. K., Chung J. H. 2009. CK2 is the regulator of SIRT1 substrate-binding affinity, deacetylase activity and cellular response to DNA-damage. PLoS One. 4, e6611.
75. Ubeda M., Habener J. F. 2003. CHOP transcription factor phosphorylation by casein kinase 2 inhibits transcriptional activation. J. Biol. Chem. 278, 40514-40520.
76. Scaglioni P. P., Yung T. M., Choi S., et al. 2008. CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor. Mol. Cell Biochem. 316, 149-154.
77. Chakraborty A., Werner J. K. Jr, Koldobskiy M. A., et al. 2011. Casein kinase-2 mediates cell survival through phosphorylation and degradation of inositol hexakisphosphate kinase-2. Proc. Natl. Acad. Sci. U. S. A. 108, 2205-2209.
78. He H., Tan M., Pamarthy D., et al. 2007. CK2 phosphorylation of SAG at Thr10 regulates SAG stability, but not its E3 ligase activity. Mol. Cell Biochem. 295, 179-188.
79. Llobet D., Eritja N., Encinas M., et al. 2008. CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells. Oncogene. 27(18), 2513-2524.
80. Channavajhala P., Seldin D. C. 2002. Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis. Oncogene. 21(34), 5280-5288.
81. Olsen B. B., Jessen V., Højrup P., et al. 2003. Protein kinase CK2 phosphorylates the Fas-associated factor FAF1 in vivo and influences its transport into the nucleus. FEBS Lett. 546, 218-222.
82. Menges C. W., Altomare D. A., Testa J. R. 2009. FAS-associated factor 1 (FAF1): Diverse functions and implications for oncogenesis. Cell Cycle. 8(16), 2528-2534.
83. Zhang L., Zhou F., van Laar T., et al. 2011. Fas-associated factor 1 antagonizes Wnt signaling by promoting {beta}-catenin degradation. Mol. Biol. Cell. 22(9), 1617-1624.
84. Cobb L. J., Mehta H., Cohen P. 2009. Enhancing the apoptotic potential of insulin-like growth factor-binding protein-3 in prostate cancer by modulation of CK2 phosphorylation. Mol. Endocrinol. 23, 1624-1633.
85. Salvi M., Xu D., Chen Y., et al. 2009. Programmed cell death protein 5 (PDCD5) is phosphorylated by CK2 in vitro and in 293T cells. Biochem. Biophys. Res. Commun. 387, 606-610.
86. Wang Y., Li X., Wang L., et al. 2004. An alternative form of paraptosis-like cell death, triggered by TAJ/TROY and enhanced by PDCD5 overexpression. J. Cell Sci. 117, 1525-1532.
87. Wang G., Ahmad K. A., Ahmed K. 2006. Role of protein kinase CK2 in the regulation of tumor necrosis factor-related apoptosis inducing ligand-induced apoptosis in prostate cancer cells. Cancer Res. 66(4), 2242-2249.
88. Olsen B. B., Petersen J., Issinger O. G. 2006. BID, an interaction partner of protein kinase CK2alpha. Biol. Chem. 387, 441-449.
89. Hellwig C. T., Ludwig-Galezowska A. H., Concannon C. G., et al. 2010. Activity of protein kinase CK2 uncouples Bid cleavage from caspase-8 activation. J. Cell Sci. 123, 1401-1406.
90. Duncan J. S., Turowec J. P., Vilk G., et al. 2010. Regulation of cell proliferation and survival: Convergence of protein kinases and caspases. Biochim. Biophys. Acta. 1804, 505-510.
91. Li P. F., Li J., Muller E. C., et al. 2002. Phosphorylation by protein kinase CK2: A signaling switch for the caspase-inhibiting protein ARC. Mol. Cell. 10, 247-258.
92. Shin S., Lee Y., Kim W., et al. 2005. Caspase-2 primes cancer cells for TRAIL-mediated apoptosis by processing procaspase-8. EMBO J. 24, 3532-3542.
93. McDonnell M., Abedin A., Melendez M. J., et al. 2008. Phosphorylation of murine caspase-9 by the protein kinase casein kinase 2 regulates its cleavage by caspase-8. J. Biol. Chem. 283, 20149-20158.
94. Guerra B., Issinger O. G. 2008. Protein kinase CK2 in human disease. Curr. Med. Chem. 15, 1870-1886.
95. Lin K. Y., Tai C., Hsu J. C., et al. 2011. Overexpression of nuclear protein kinase CK2 α catalytic subunit (CK2α) as a poor prognosticator in human colorectal cancer. PLoS One. 6, e17193.
96. Giusiano S., Cochet C., Filhol O., et al. 2011. Protein kinase CK2α subunit over-expression correlates with metastatic risk in breast carcinomas: Quantitative immunohistochemistry in tissue microarrays. Eur. J. Cancer. 47, 792-801.
97. Lin K. Y., Fang C. L., Chen Y., et al. 2010. Overexpression of nuclear protein kinase CK2 beta subunit and prognosis in human gastric carcinoma. Ann. Surg. Oncol. 17, 1695-1702.
98. Pinna L. A., Allende J. E. 2009. Protein kinase CK2 in health and disease. Protein kinase CK2: An ugly duckling in the kinome pond. Cell Mol. Life Sci. 66, 1795-1799.
99. Ruzzene M., Tosoni K., Zanin S., et al. 2011. Protein kinase CK2 accumulation in "oncophilic" cells: Causes and effects. Mol. Cell Biochem. PMID: 21735095.
100. Battistutta R. 2009. Protein kinase CK2 in health and disease: Structural bases of protein kinase CK2 inhibition. Cell Mol. Life Sci. 66, 1868-1889.
101. Niefind K., Issinger O. G. 2010. Conformational plasticity of the catalytic subunit of protein kinase CK2 and its consequences for regulation and drug design. Biochim. Biophys. Acta. 1804(3), 484-492.
102. Hanif I. M., Hanif I. M., Shazib M. A., et al. 2010. Casein kinase II: An attractive target for anti-cancer drug design. Int. J. Biochem. Cell Biol. 42(10), 1602-1605.
103. Sarno S., Papinutto E., Franchin C., et al. 2011. ATP site-directed inhibitors of protein kinase CK2: An update. Curr. Top. Med. Chem. 11(11), 1340-1351.
104. Cozza G., Meggio F., Moro S. 2011. The dark side of protein kinase CK2 inhibition. Curr. Med. Chem. 18(19), 2867-2884.
105. Battistutta R., Cozza G., Pierre F., et al. 2011. Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical stage for the treatment of cancer. Biochemistry. PMID: 21870818.
106. Siddiqui-Jain A., Drygin D., Streiner N., et al. 2010. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 70(24), 10288-10298.
107. Ferguson A. D., Sheth P. R., Basso A. D., et al. 2011. Structural basis of CX-4945 binding to human protein kinase CK2. FEBS Lett. 585(1), 104-110.
108. Pierre F., Chua P. C., O'Brien S. E., et al. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer. Mol. Cell Biochem. PMID: 21755459.